Griseofulvin
- Atc Codes:D01AA08#D01BA01
- CAS Codes:126-07-8
- PHARMGKB ID:126-07-8
Table of contents
- Brand Names
- Drug Combinations
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Toxicological Effects
- Genes that may be involved
- Induces
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Cyprus: Grisal, Griseofulvin, Medofulvin, Syntofulvin; France: Grisefuline; Germany: Fulcin, Griseo CT, Likuden; Ireland: Grisol; Italy: Fulcin, Griseofu FN, Grisovina; Luxembourg: Griseofulvin; Malta: Griseofulvin; Poland: Grizin; Spain: Fulcin.
North America
USA: Grifulvin, Gris-PEG, Griseofulvin.
Latin America
Argentina: Grisovin FP; Brazil: Fulcin, Sporostatin; Mexico: Fulcin, Fulsivin, Grisovin.
Asia
Japan: Griseofulvin SG, Grisetin V, Guservin FP, Poncyl-FP.
Drug combinations
Griseofulvin, Boric Acid, Econazole, Hydrocortisone, Neomycin and Salicylic Acid
Griseofulvin, Diflorasone, Econazole, Gentamicin, Hydrocortisone, Neomycin, and Salicylic Acid
Chemistry
Griseofulvin: C~17~H~17~ClO~6~. Mw: 352.77. (1) Spiro[benzofuran-2(3H),1′-[2]cyclohexene]-3,4′-dione, 7-chloro-2′,4,6-trimethoxy-6′-methyl-, (1’S-trans)-; (2) 7-Chloro-2′,4,6-trimethoxy-6’β-methylspiro[benzofuran-2(3H),1′-[2]cyclohexene]-3,4′-dione. CAS-126-07-8.
Pharmacologic Category
Miscellaneous Antifungals. (ATC-Code: D01AA08; D01BA01).
Mechanism of action
Antifungal antibiotic produced by Penicillium. Inhibits fungal cell mitosis at metaphase. Binds to human keratin making it resistant to fungal invasion.
Therapeutic use
Treatment of dermatophytoses of skin, scalp, and nails, including Tinea barbae (ringworm of bearded areas of face and neck), Tinea capitis (scalp ringworm), Tinea corporis (ringworm of the body), Tinea cruris (jock itch; groin ringworm), Tinea pedis (athlete’s foot, foot ringworm), and Tinea unguium (onychomycosis; nail ringworm) caused by Trichophyton, Microsporum, or Epidermophyton floccosum.
Pregnancy and lactiation implications
Animal studies have shown decreased spermatogenesis, as well as embryotoxic and teratogenic effects with griseofulvin. There are no adequate, well-controlled studies in pregnant women. Use during pregnancy is contraindicated.
Unlabeled use
Contraindications
Hypersensitivity to griseofulvin or any component of the formulation. Severe liver disease. Porphyria (interferes with porphyrin metabolism). Pregnancy.
Warnings and precautions
Hypersensitivity cross-reaction between penicillins and griseofulvin possible. May cause fetal harm when administered to pregnant women. Hypersensitivity reactions (e.g. rash, urticaria, erythema multiforme-like reactions, angioneurotic edema) reported. Photosensitivity reactions reported. Lupus erythematosus may be aggravated if photosensitivity reaction occurs. Should not be used for treatment of pityriasis (tinea) versicolor, cutaneous Candida infections, or systemic fungal infections (including blastomycosis, candidiasis, chromoblastomycosis, coccidioidomycosis, cryptococcosis, histoplasmosis, or sporotrichosis). Use should also be avoided in treatment of bacterial infections, including actinomycosis or nocardiosis. Contraindicated in hepatocellular failure.